Enzyme

Codexis to Report Third Quarter 2021 Financial Results on November 4

Thursday, October 21, 2021 - 9:05pm

REDWOOD CITY, Calif., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq:CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced that it will report its financial results for the third quarter of 2021 on Thursday, November 4, 2021, following the close of market.

Key Points: 
  • REDWOOD CITY, Calif., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq:CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced that it will report its financial results for the third quarter of 2021 on Thursday, November 4, 2021, following the close of market.
  • Codexis management will host a conference call and webcast at 4:30 p.m. Eastern Time to discuss the Companys financial results and provide a business update.
  • Participants may access the live webcast on the Codexis Investor Relations website , where it will be archived for 90 days.
  • Codexis expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law.

Global RNA Analysis Market Research Report 2021 - ResearchAndMarkets.com

Thursday, October 21, 2021 - 3:11pm

The "Global RNA Analysis Market 2021-2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global RNA Analysis Market 2021-2026" report has been added to ResearchAndMarkets.com's offering.
  • RNA species (messenger RNA, transfer RNA, and ribosomal RNA) play an important role in the translation of genetic information from DNA to proteins.
  • This report explores the present and future market values of the RNA analysis market, particularly by type of analysis such as microarrays, polymerase chain reaction (PCR), sequencing technologies, and RNAi gene silencing.
  • Also included in the report is a discussion of the impact of COVID-19 on the market and profiles of leading companies in the RNA analysis market.

Nurix Therapeutics to Participate in the 4th Annual Targeted Protein Degradation Summit

Thursday, October 21, 2021 - 12:00pm

SAN FRANCISCO, Oct. 21, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq:NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that Nurixs president and chief executive officer Arthur T. Sands, M.D., Ph.D., and Nurixs chief scientific officer Gwenn M. Hansen, Ph.D., will participate in several sessions of the 4th Annual Targeted Protein Degradation (TPD) Summit, which will be held virtually October 26-29, 2021.

Key Points: 
  • SAN FRANCISCO, Oct. 21, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq:NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that Nurixs president and chief executive officer Arthur T. Sands, M.D., Ph.D., and Nurixs chief scientific officer Gwenn M. Hansen, Ph.D., will participate in several sessions of the 4th Annual Targeted Protein Degradation (TPD) Summit, which will be held virtually October 26-29, 2021.
  • Nurixs drug discovery approach is to either harness or inhibit the natural function of E3 ligases within the ubiquitin proteasome system to selectively decrease or increase cellular protein levels.
  • Nurixs wholly owned pipeline includes targeted protein degraders of Brutons tyrosine kinase, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene B, an E3 ligase that regulates T cell activation.
  • Although Nurix believes the expectations and assumptions reflected in such forward-looking statements are reasonable, Nurix can give no assurance that they will prove to be correct.

DNA Script Appoints Don Kania as Chairman of the Board of Directors, Catherine Moukheibir as Audit Chair and Bonnie Anderson as Independent Director

Thursday, October 21, 2021 - 10:00am

DNA Script, a leader in Enzymatic DNA Synthesis (EDS), today announced the appointment of Don Kania, Ph.D. as Chairman of the Board of Directors, Catherine Moukheibir as Audit Chair and Bonnie Anderson as independent new members of the Board.

Key Points: 
  • DNA Script, a leader in Enzymatic DNA Synthesis (EDS), today announced the appointment of Don Kania, Ph.D. as Chairman of the Board of Directors, Catherine Moukheibir as Audit Chair and Bonnie Anderson as independent new members of the Board.
  • The life sciences industry is in the process of revolutionizing our world, starting with healthcare and expanding into other markets.
  • Moukheibir brings over 30 years of leadership experience in finance, capital markets and life sciences to DNA Script.
  • DNA Script is at a pivotal point with the targeted commercial launch of our SYNTAX Platform, said Thomas Ybert, DNA Script co-founder and CEO.

Recreate The Spa Experience at Home with SONAGE

Tuesday, October 19, 2021 - 10:10pm

If you can't actually go to the spa, we can bring the spa to you.

Key Points: 
  • If you can't actually go to the spa, we can bring the spa to you.
  • "Sonage is helping clients recreate the spa experience at home.
  • A safe and gentle chemical peel at home that will renew your skin cells without a trip to the spa.
  • Sonage Skincare advocates a holistic lifestyle, curating routines for that familiar spa feeling - leaving your skin glowing and your mind calm.

NIH Lists Enzyme & Probiotic Combo On Dietary Supplements In The Time Of COVID-19 Fact Sheet For Health Professionals

Tuesday, October 19, 2021 - 7:26pm

CHINO, Calif., Oct. 19, 2021 /PRNewswire/ --Specialty Enzymes & Probiotics is pleased to share that the National Institute of Health (NIH) Office of Dietary Supplements has included ImmunoSEB and ProbioSEB CSC3 in its Fact Sheet for Health Professionals: Dietary Supplements in the Time of COVID-19 .

Key Points: 
  • CHINO, Calif., Oct. 19, 2021 /PRNewswire/ --Specialty Enzymes & Probiotics is pleased to share that the National Institute of Health (NIH) Office of Dietary Supplements has included ImmunoSEB and ProbioSEB CSC3 in its Fact Sheet for Health Professionals: Dietary Supplements in the Time of COVID-19 .
  • "Our mission is to create powerful natural products to promote good health, and we've done that with this potent enzyme and probiotics combo."
  • The Probiotics section of the NIH Dietary Supplement Fact Sheet for Health Professionals highlights the promising results of a recently published clinical trial on ImmunoSEB and ProbioSEB CSC3 in the journal Medicines.
  • In the trial, people experiencing muscle weakness and brain fog post COVID-19 were treated with the enzyme and probiotic combo for 14 days.

BASF and Cargill expand partnership to develop and market innovative enzyme-based solutions for the animal feed industry

Tuesday, October 19, 2021 - 1:00pm

The goal is to bring farmers feed innovations that reduce nutrient waste, improving feed efficiency, and promote animal growth and wellbeing.

Key Points: 
  • The goal is to bring farmers feed innovations that reduce nutrient waste, improving feed efficiency, and promote animal growth and wellbeing.
  • Through joint solutions we will further increase the value creation opportunities in the enzymes space," says Julia Raquet, Senior Vice President BASF Animal Nutrition & Aroma Ingredients.
  • "Together, BASF and Cargill are bringing forward market solutions that target zero nutrient waste and address customers' major productivity and sustainability challenges.
  • The direct relationship with producers allows Cargill to develop solutions that provide foundational economic and environmental benefits to their operations.

Purigen Biosystems Enables Scientists to Extract and Purify Higher Yields of DNA from Fresh Frozen Tissue Samples

Tuesday, October 19, 2021 - 1:03pm

Purigen Biosystems, Inc. , a leading provider of next-generation technologies for extracting and purifying nucleic acids from biological samples, today announced the launch of the Ionic Tissue to Pure DNA Kit.

Key Points: 
  • Purigen Biosystems, Inc. , a leading provider of next-generation technologies for extracting and purifying nucleic acids from biological samples, today announced the launch of the Ionic Tissue to Pure DNA Kit.
  • The new kit allows users of the Ionic Purification System to extract increased yields of high-quality DNA from fresh frozen biological samples with a simple, automated workflow.
  • View the full release here: https://www.businesswire.com/news/home/20211019005342/en/
    Purigen Biosystems' automated Ionic Tissue to Pure DNA Kit recovers more than three times the amount of high-quality nucleic acid from limited samples compared to leading column-based products.
  • (Photo: Business Wire)
    The Ionic Tissue to Pure DNA Kit consistently provides more than three times higher DNA yields compared to leading column-based kits.

Global Metastatic Breast Cancer Pipeline Insight Report 2021: Focus on 100+ Companies and 100+ Pipeline Drugs - ResearchAndMarkets.com

Monday, October 18, 2021 - 3:49pm

This "Metastatic Breast Cancer - Pipeline Insight, 2021" report provides comprehensive insights for about 100+ companies and 100+ pipeline drugs in Metastatic Breast Cancer pipeline landscape.

Key Points: 
  • This "Metastatic Breast Cancer - Pipeline Insight, 2021" report provides comprehensive insights for about 100+ companies and 100+ pipeline drugs in Metastatic Breast Cancer pipeline landscape.
  • The companies and academics are working to assess challenges and seek opportunities that could influence Metastatic Breast Cancer R&D.
  • The therapies under development are focused on novel approaches to treat/improve Metastatic Breast Cancer.
  • This segment of the Metastatic Breast Cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery.

Global Microbial Products in Home & Personal Care Market Outlook to 2026: Huge Opportunity for Environmentally Friendly Products - ResearchAndMarkets.com

Monday, October 18, 2021 - 1:34pm

The "Global Microbial Products in Home & Personal Care Market Outlook to 2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Microbial Products in Home & Personal Care Market Outlook to 2026" report has been added to ResearchAndMarkets.com's offering.
  • The global Microbial Products in Home & Personal Care market is expected to witness a significant growth rate during the forecast period.
  • The market for global microbial products is being driven by increasing demand from personal care industries for products like bio-surfactant, vitamins, antioxidants, pigments, enzymes, and peptides.
  • Personal care products like bath & shower, hair care, and oral care have higher penetration and acquire approximately half of the total market share.